Human tissue is a precise and rigorous whole composed of various cells, a specific structure, and its surrounding microenvironment. The cell line model and xenograft animal model are the most commonly used research models, which provide a platform for the development of medicine. However, the complexity of physiological and pathological responses between a single cell line and humans with multiple cells is unparalleled. There is species specificity between the physiological and pathological responses of humans and other animals. However, their limitations cannot meet the needs of all research kinds. Thus, there is an urgent need for a model that conforms to the human physiological and pathological environment as much as possible for scientific research (Table 1).

In 1907, Harrison inoculated isolated frog embryo medulla tissue onto frog lymph blocks, thus opening up an experimental method of cultivating cells on glassware. This experimental method is the beginning of tissue culture technology, from which cell lines became inseparable from the development of medicine. Cell lines have remarkable advantages. For example, they are inexpensive, easy to maintain, and expand, and the technology is relatively simple. Cell lines are suitable for high-throughput drug screening, and multiple cell line populations with histological and genetic changes can simulate different clinical situations and drug responses (Iorio et al., 2016; Lee et al., 2018a). Cell lines are also suitable for gene editing (Tang et al., 2016; Liao et al., 2017; Xia et al., 2017). Through superior gene editing, significant progress was made in discovering carcinogenic and molecular targets in vitro. Therefore, cell lines are the most widely used research model in the past few decades, as they play an irreplaceable role in disease development research and drug screening.

However, the cell line model has two main limitations. The cell line consists of a single cell, likely representing a subgroup of research objects (Ben-David et al., 2018). First, cell line survival is affected by pressure that is highly sensitive to culture conditions, and persistent instability can quickly lead to the heterogeneity of the cell line. With time, the cell line finally loses the ability to generalize the heterogeneity of the original tissue. Second, the cell line model has two-dimensional (2D) growth, with neither external signals from adjacent cells nor distal external signals from the circulatory system. Therefore, this model cannot reflect vital structures and microenvironments that usually occur under specific physiological or pathological conditions. For example, in tumor development, microenvironmental factors such as blood and lymphatic system (Mazzone and Bergers, 2019), surrounding fibroblasts (Hussain et al., 2020), and mechanical stimulation (Sewell-Loftin et al., 2020) affect the behavior and molecular characteristics of cancer cells and thus change the invasive ability of cancer, resistance to chemotherapy, and growth in vivo. Given these main limitations, traditional cell line disease models often misestimate the disease development and treatment response in vivo, which seriously limits the application of cell line models in experimental research.

PDX are the most common tumor models established by transplanting human tumor tissues/cells in animal hosts (usually immunodeficient or humanized mice) (Lai et al., 2017). The first patient-derived tumor xenograft animal model was established in the 1950s (Toolan, 1953). In research using PDX model, the aim was to obtain a group of animals with diseases similar to those of humans and conduct medical experiments to obtain preclinical results (Byrne et al., 2017). PDX can grow in a 3D microenvironment rich in nutrients and oxygen, can interact and communicate with the host matrix and immune cells, and can maintain the original 3D structure of the tumors and original genomic and phenotypic characteristics. Therefore, they are more suitable for use in predicting drug responses (Gao et al., 2015; Drapkin et al., 2018) and in preclinical host trials (Farago et al., 2019; Savaikar et al., 2020) and for testing the efficacy of new strategies (Stewart et al., 2017). Based on the above advantages, PDX have excellent predictive value and are indispensable for result authentication in essential clinical experiments.

However, the PDX model still has some limitations. PDX models are more time-consuming and expensive than other research models. Moreover, experiments using PDX require ethical approval and consideration of animal welfare and are strictly regulated (Biller-Andorno et al., 2015). With tumor subcultures, mouse stromal cells will replace the primitive human stromal cells and immune cells (Braekeveldt et al., 2016). During the administration of PDX, PDX-specific copy number alterations gradually disappear and primitive heterogeneity was lost (Ben-David et al., 2017; Ben-David et al., 2019). The genomic map and tumor microenvironment will affect treatment response. In the era of targeted and precision therapy, clinical results are inconsistent with the results of animal experiments, which lower the predictive value of PDX.

Given the limitations of cell lines and PDX, scientists constantly aim to construct a new research model, which has the advantages of both cell lines and PDX. Until 2009, Sato et al. (2009) first described an organoid culture system that allows ISCs to expand in vitro for a long time in a 3D extracellular matrix (ECM), which opened the prelude to the new era. In the past 10 years, organoids are extensively applied to understand stem cell biology, organogenesis, and human pathology and made considerable breakthroughs in disease mechanism research, drug screening, and precision treatment.

Organoids have significant advantages, as they require relatively less time and money but offer a high success rate. Organoids retain the 3D structure of the original tissues, faithfully summarizing the genetic and phenotypic heterogeneity of the original tissue (Cristobal et al., 2017). Organoids can be a platform in screening drugs with high efficiency and sensitivity, guiding clinical precision treatment and personalized treatment (Pauli et al., 2017). Organoids are also suitable for gene editing. For example, combining the CRISPR–Cas9 system and organoids provides a new opportunity to study tumor gene mutation (Drost et al., 2017). Organoids can be transformed into other models (Jian et al., 2020), cooperate and construct a biological bank (biobank) (Kim et al., 2019; Zhang et al., 2021), to establish a comprehensive and accurate experimental platform. However, organoids still have limitations. Thus, the second half of this review will focus on the current predicament and future development.

As a new research model and development platform, organoids fill the gap between the cell line and PDX (Figure 1), support the existing model system, and extend basic biological research, medical research, and drug discovery to the human environment related to physiology. In the future, the study of organoids has a broad prospect, and an increasing number of scientists will pay attention to organoids and combine them more widely and deeply with various fields of medical research.

In the past 10 years, organoids break through the simple physical contact between cells and form closer biological communication; i.e., organoids break through the dilemma that it is difficult for PDX to replicate physiological processes that exist only in humans. Moreover, we will take cancer, infectious diseases, genetic diseases, and regenerative medicine as examples to show the potential of organoids and attract more scholars to use this technology in the future.

Cancer is a significant health problem worldwide. Scientists predict that the incidence of all cancer types will increase from 12 million in 2008 to 22 million by 2030 (Berkers et al., 2019). The incidence of and mortality from cancer increase in developing countries, so cancer research has a long way to go (Feng et al., 2019). We have performed much in-depth investigation on the origin, pathology, and genetics of cancer in the past few decades, and we found that the knowledge gained from cell lines and PDX is not entirely consistent with the actual clinical situation. We are increasingly aware that cancer has different heterogeneity and plasticity; thus, how to treat it accurately is very important to the survival and prognosis of patients with cancer. The recently developed 3D culture technology has led to the development of new and more physiological organoids, thus creating new and more targeted therapies. In the more than 10 years since the emergence of organoids, scientists successfully cultivated all kinds of tumor organoids, such as bladder cancer (Lee et al., 2018b), colorectal cancer (van de Wetering et al., 2015), lung cancer (Dijkstra et al., 2020), liver cancer (Nuciforo et al., 2018), prostate cancer (Puca et al., 2018), breast cancer (Han et al., 2020), gastric cancer (Yan et al., 2018), pancreatic cancer (Seino et al., 2018), lymphatic cancer (Tian et al., 2015), esophageal cancer (Li et al., 2018), thyroid cancer (Sondorp et al., 2020), among others (Figure 2). These studies have shown that tumor organoids are highly similar to the original tumors in terms of genetic specificity, epigenetic characteristics, morphology, metabolism, proliferation rate, and metastatic potential. Moreover, organoids build a more suitable platform for exploring new therapeutic targets and high-throughput screening of drugs.

For example, in lung cancer, the global estimates of cancer morbidity and mortality compiled by the International Agency for Research on Cancer in 2018 show that lung cancer is the most common cancer (accounting for 11.6% of total cases) and the leading cause of cancer death (18.4% of total cancer deaths). There are 2.1 million new cases and 1.8 million deaths annually (Bray et al., 2018). The emergence of organoids brings new impetus to the research of lung cancer.

Lung cancer has various manifestations, and whether organoids can reproduce the unique tissue structure and epigenetics of patients is the first problem to address. In one study, the structure of the organoids of patients with lung cancer ranged from thin-walled cystic structures to dense spherical cell clusters, containing 50% mutations, and more than 70% of the cells expressed acetaldehyde dehydrogenase, which maintained the biological characteristics of tumor biopsies (Jung et al., 2019). Once the primary lung cancer tissue is obtained, organoids can be continuously regenerated and replicated in vitro, and the cytological characteristics of the tumor remain stable. The clinical markers remained unchanged during the passage, which lays a foundation for follow-up research. For lung cancer types in which patient samples are lacking, gene editing is combined with organoids to create new possibilities. Some scholars used the CRISPR–Cas9 system to edit multiple genes in lung organoids and showed that the transfected organoids expressed primary cell-specific markers of lung squamous cell carcinoma, such as cytokeratin 5, p63, and epithelial cell adhesion molecule. This kind of gene-edited organoids can be applied in immune checkpoint therapy combined with drug-screening platforms (Hai et al., 2020). Gene editing is a feasible method for rapid mass production of organoids, and this significantly facilitates lung cancer research. However, gene editing can lead to mutations, instability, and uncertainty. Thus, whether the tumor organoids obtained by gene editing are entirely consistent with the source patients is a question worth considering. Drug screening is a strict demonstration process, and the effect of drugs screened through organoids needs to be verified by more experiments. Moreover, this process provides us with an economical and rapid method of studying the critical targets of the tumor.

Drug development and screening is a rigorous and essential process. In the past, PDX have been used as the last barrier before clinical trials. However, the complexity and high cost of PDX limit large-scale drug trials. A current comparative study of non-small cell lung cancer showed that the sensitivity of KRAS-mutant organoids to the MEK inhibitor trametinib was consistent with the relative PDX model. By contrast, organoids without KRAS mutations were as resistant as relative PDX (Shi et al., 2020a). This finding suggests the feasibility of replacing PDX with organoids as a drug testing platform, which significantly reduces the cost of large-scale screening. As an in vitro model, organoids still lack many mechanisms that affect drug responses, such as drug metabolism and tissue infiltration; thus, confirming the consistency and effectiveness of the organoids’ response to drugs in vivo and in vitro is important. Wang et al. established a 15 patient-derived non-small cell lung cancer organoid model with human epidermal growth factor receptor 2 mutation. Drug screening for those organoids shows that pirotinib had a more significant inhibitory effect on organoid proliferation than afatinib in vitro. In the final clinical trial, the results were the same as drug screening of organoids, and pirotinib showed good efficacy (Wang et al., 2019). This study shows that organoids are more feasible in clinical tumor treatment and can help shorten the absolute distance between clinic and laboratory. Considering that lung cancer has various biological and molecular subtypes, genetic heterogeneity is an essential factor that affects the response to drug therapy. We still need to establish biobanks with a large number of data. The era of single-drug treatment for all patients has passed, and the future focuses on the era of personalized and accurate treatment. Organoids have a great application prospect in biobanks. Kim et al. established a biobank derived from 80 lung cancer organoids. The organoid biobank covers more than 95% of lung cancer types, including adenocarcinoma, squamous cell carcinoma, small cell carcinoma, adenosquamous cell carcinoma, and large cell carcinoma. They screened targeted drugs such as docetaxel, olaparib, erlotinib, and crizotinib, showing that organoid biobanks can predict patient-specific drug responses in vitro as well as proof-of-concept studies of new targeted drugs based on genetic changes (Kim et al., 2019). The development of organoid models is significantly conducive to drug development and screening. In the future, we also need to increase the sample size of organoid biobank. Through multi-omics technology to analyze tumor organoids, coupled with large-scale drug screening, data are analyzed by artificial intelligence. Finally, the multi-omics data of tumor organoids are related to drug sensitivity and realize personalized and accurate treatment.

By understanding the biology of tumor organoids and apply them in clinical practice, a preclinical cancer model is needed. We have discussed the main characteristics and application of organoid technology in cancer. Although it is still in the early stage of exploration, the prospect is up and coming. The results of this series of organoid studies on various cancers continue to send us a clear message: Tumor organoids can maintain the phenotype and genetic heterogeneity of the primary tumor. Tumor organoid research can deepen our understanding of the mechanism of tumorigenesis and provide a possible method of treating tumors. Moreover, organoids can carry out high-throughput drug screening and contribute to the development of precise and personalized treatment.

Approximately 5.3% of infants will suffer from genetic diseases when followed up until age 25 years (Verma and Puri, 2015). Many genetic diseases take time to develop in a specific tissue microenvironment, and a traditional single cell line cannot simulate these diseases. In addition, xenograft models do not entirely simulate the characteristics of genetic diseases in humans, such as diseases that affect neurodevelopment and the brain. Thus, further research on cell lines and xenografts in genetic diseases is not needed. Organoids can summarize the organ’s structure and function and retain the tissue’s original genetic and epigenetic state, which are suitable for gene editing. These aspects are crucial for modeling genetic diseases caused by one (single gene) or multiple (multifactor) abnormalities.

Genetic diseases are mainly caused by mutations of various genes, which make it difficult for cell lines and xenografts to simulate these genetic diseases. Thus, the best choice is to use organoids from the source patient (Table 2). Cystic fibrosis (CF) is an autosomal recessive hereditary disease. The imbalance of chloride channels controlled by transmembrane conductor receptors affects the epithelial cells of many organs such as the lung, pancreas, sweat gland, liver, kidney, and intestine. The corresponding imbalance results in pancreatic insufficiency, gastrointestinal symptoms, and progressive lung diseases. In the past, symptomatic treatments, such as mucolytic agents, anti-inflammatory drugs, and antibiotics, were employed (Villanueva et al., 2017). Because organoids perfectly maintain the genetic specificity of the source tissue, the research on organoid technology to unravel the complex molecular mechanisms and drug screening has increased. Herein, we focused on the breakthrough in CF owing to the combination of organoids and gene-editing technology. The combination of organoids and gene-editing technology brings new hope for the complete cure of CF. In 2013, Schwank et al. used the CRISPR–Cas9 genome-editing system to correct the site of the CF transmembrane conductor receptor (CFTR) through homologous recombination in CF patient-derived intestinal and colonic organoids, and this provided a theoretical basis for gene correction by homologous recombination in primary ASCs from patients with single-gene hereditary defects (Schwank et al., 2013). Subsequently, gene editing corrected proximal lung organoids and patient-derived adenocarcinoma cell line CFPAC-1 (Ruan et al., 2019), intestinal organoids, and airway epithelial cells from patients with CF (Maule et al., 2019), and nasal mucosa of CF mice and patient-derived small intestinal organoids (Dekkers et al., 2013; Vidović et al., 2016). The chloride channel has been effectively repaired and specific function restored, which shows the feasibility of implanting the edited organoids back into the body. In a recent study, Maarten et al. described a biobank of CF intestinal organoids, representing 664 patients, and believed that 20% of them could theoretically enable efficient repair of nonsense mutations in CFTR through adenine base editors (Geurts et al., 2020). Although gene-edited organoids have made some achievements in animal models, their efficiency is very low, and the success rate is not high. More importantly, the safety, long-term stability, and functionality of gene-edited organoids should be tested over time.

With the establishment and application of organoids, this 3D method has been developed rapidly in basic research and transformation research of genetic diseases. Organoids and gene editing show the potential to completely cure CF, and CF may 1 day be cured by this technique. Organoids create an exciting new opportunity for human genetic diseases in vitro and bring the dawn for the final cure of genetic diseases through gene-editing technology.

Research on human infectious diseases is limited by the lack of normal human physiological and pathophysiological functional models. In the traditional research model, the classical single-cell culture system cannot reproduce complex and dynamic responses or cell-cell interactions. Xenograft animal models may respond similarly to human models, but species-specific differences may lead to an unfaithful display of disease cycles and human responses. The application of organoids allows for the examination of complex physiological or pathological processes in more similar structures under in vivo conditions and paves the way for studying infection and host–source interaction (Figure 3). A model of the interaction among parasites, bacteria, viruses, and other pathogens and their hosts has been established, such as cryptosporidium and small intestine and lung organoids (Heo et al., 2018), Zika virus and brain organoids (Cugola et al., 2016), hepatitis B virus and functional liver organoids (Nie et al., 2018), and Salmonella typhimurium and intestinal organoids (Forbester et al., 2018).

Regarding severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as of July 2021, nearly 180 million cumulative cases and more than 4 million deaths were confirmed worldwide. Common symptoms of coronavirus disease 2019 (COVID-19) include fever, cough, and shortness of breath, and the most common cause of death is respiratory failure, combined with metabolic complications in other body systems, including the cardiac, renal, nervous, and gastrointestinal systems (Wiersinga et al., 2020). Patient-derived organoids have various cell types, molecular expression patterns, genetic markers, etc., contained in the corresponding body organs, which can simulate the pathogenic process of human infection, reflect the whole process of infectious diseases intuitively, and provide the possibility for studying the characteristics of pathogens and the interaction between human hosts and pathogens. With the recent SARS-CoV-2 pandemic, determining appropriate therapeutic drugs is the top priority. Han et al. developed human pluripotent stem cells lung organoids (hPSC-LOs) for SARS-CoV-2 and SARS-CoV-2 colon organoids (hPSC-COs), and high-throughput screening showed that imatinib, mycophenolic acid, and quinacrine dihydrochloride significantly inhibited SARS-CoV-2 (Han et al., 2021). This indicates the use of SARS-CoV-2-infected hPSC-LOs and hPSC-COs as valuable research models for screening drugs to identify candidate therapeutic agents for COVID-19. In addition, scientists have established models of common complications in patients with SARS-CoV-2 infection, for example, the SARS-CoV-2 infection of a human intestinal organoid model (Lamers et al., 2020; Stanifer et al., 2020; Zhou et al., 2020), SARS-CoV-2 infection of a human renal organoid model (Monteil et al., 2020; Xia et al., 2020), SARS-CoV-2 infection of a human brain organoid model (Jacob et al., 2020; Ramani et al., 2020), and SARS-CoV-2 infection of a human liver organoid model (Schultz et al., 2020; Yang et al., 2020; Zhao et al., 2020). These models laid the foundation for the organoid biobanks of SARS-CoV-2 infection, which provide valuable models for drug screening and evaluation of antiviral therapy. With the use of increasingly different SARS-CoV-2 infection organoids, we will know more about the characteristics and disease mechanism of SARS-CoV-2 from different aspects.

In addition to existing drug screening, novel drug development and drug combinations are top priorities of research. SARS-CoV-2 uses angiotensin-converting enzyme 2 (ACE2) and transmembrane serine protease 2 as the main entry point into host cells (Ziegler et al., 2020), and as confirmed in related organoids (Mahalingam et al., 2021), many studies on drug developments have focused on these two targets. Some scientists have designed a humanized decoy antibody (ACE2-Fc fusion protein) that neutralizes SARS-CoV-2 infection, transforming angiotensin II (Ang II) into Ang II–VII and activating natural killer cells (Huang et al., 2021). This antibody may be applied in health care workers or high-risk groups to prevent SARSCoV-2 infection. In the combination drug therapy, anti-androgen drug therapy can reduce the expression of ACE2 and protect hESC-derived lung organoids from SARS-CoV-2 infection (Samuel et al., 2020). Combining human-recombinant soluble ACE2 or human neutralizing antibody with remdesivir effectively inhibits SARS-CoV-2 replication and significantly improves efficacy (Pei et al., 2020; Monteil et al., 2021). Because of the excellent characteristics of organoid models, the drugs and treatment methods developed using SARS-CoV-2 infection organoids are believed to be more reliable and effective, so clinical trials are conducted more quickly.

Organoids are different from cell lines and xenograft animal models and ideally represent all the cellular components of organs of specific species. Theoretically, they are very suitable for investigating infectious diseases, especially those caused by pathogens. Considering the toxicology of drugs, it will be more reasonable to transplant organoids into animal models and then verify the efficacy of related drugs. Organoids bring about a new method of drug screening, treatment, and vaccine of COVID-19, which will help contain the pandemic.

Regenerative medicine applies biological and engineering theories and methods to restore lost or functionally damaged tissues and organs. Regenerative medicine restores the function of tissues or organs in patients with severe injury or chronic diseases. Tissue regeneration and repair face three main problems, namely, donor shortage (Dwyer et al., 2021), immune rejection (Loupy and Lefaucheur, 2018), and ethical issues (Lieber et al., 2018), promoting the search for alternatives. Organoids can be derived from the patient’s PSCs and ASCs. They rapidly reproduce in vitro and retain the 3D structure, function, heredity, and phenotypic specificity of the original tissues. These advantages are essential for transplantable, immune, and functional tissues or organs in vitro, which undoubtedly brings a new dawn for regenerative medicine (Table 3).

As a valuable tool for the research and treatment of intestinal diseases, intestinal organoids are the most promising direction in organoid regenerative medicine research. In the beginning, small intestinal organoids derived from stem cells were transplanted into the mouse intestinal model, and epithelial crypt-like structures, villi, and Paneth cells were found, which had the characteristics of the primitive intestines (Fordham et al., 2013; Fukuda et al., 2014). That study points to the future opportunities for specific gastrointestinal regeneration in patients, and scientists made various efforts in this direction. Others found that intestinal organoids derived from genetically programmed cells had ISC properties. Organoids transplanted into the damaged colon resembled morphologically and functionally at least 3 months (Miura and Suzuki, 2017). Furthermore, Sugimoto et al. established an orthotopic xenograft system for normal human colonic organoids, enabling the stable reconstruction of human colonic epithelium in vivo for more than 10 months (Sugimoto et al., 2018). Organoid transplantation is a rigorous technique that needs time testing. However, whether the implanted organoids can be thoroughly combined with the primary tissues and maintain long-term functional stability still needs further investigation. All the aforementioned studies have shown the importance of organoids in regenerative medicine. However, the application of organoids in human transplantation still requires a suitable stent, which is necessary to reduce tissue rejection and incompatibility. Scientists designed synthetic hydrogels with a four-armed, maleimide-terminated poly (ethylene glycol) (PEG) macromer starting with the carrier (Cruz-Acuña et al., 2017). Synthetic hydrogels support the growth and expansion of human intestinal organoids in vitro and can be used as injection carriers for transport to the damaged intestinal mucosa to promote the healing of an intestinal injury. Organoid transplantation carriers should have the following characteristics: biocompatibility, nontoxicity to the human body and organoids, suitable viscosity, easy to use, and remain in the tissue defect for a long time. In addition, the structure facilitates the connection between organoids and primary tissues.

Owing to the cultivation of various kinds of patient-derived organoids in vitro, we can skillfully avoid or solve donor shortage, immune rejection, and ethical problems in regenerative medicine. At present, the size and proportion of organoids are still a problem in regenerative medicine. Most organoids are still in micron size and have no vascular system and peripheral immune microenvironment; thus, a large-scale reorganization experiment on organoids is required. Moreover, whether an organoid can be combined with the target tissue and form a standard functional unit is the criterion for successful implantation. However, whether the proportion of all cell kinds in organoids is consistent with that of the target tissue and whether it can be maintained during proliferation and differentiation are questions to consider. In the future, continuous development and improvement of organoids will create conditions for organ expansion in vitro, functional transplantation into patients, and reconstruction of tissue defects.

Organoids can be cultured by ESCs (Moris et al., 2020), iPSCs (Xie et al., 2020), ASCs (Huch et al., 2015), or tumor stem cells (Shimokawa et al., 2017) under suitable culture conditions in vitro. The cultivation of different organoids requires corresponding cytokines and culture matrices to form a specific microenvironment. The most commonly used culture conditions of organoids have two parts: 1) hydrogels, which are a 3D scaffold for organoid culture that promote the aggregation of 3D-cultured cells and produce the polarity of cell arrangement, and (Simian and Bissell, 2017) cell growth regulatory components, which simulate the ecological conditions of organs in the body, providing various information to maintain the ability of stem cells to self-renew, proliferate, and differentiate.

The gold standard for cultivating organoids is to simulate the tissue microenvironment in the body as much as possible. Compared with the dynamic microenvironment in vivo, the aforementioned conventional culture conditions of organoids are insufficient, and many key factors are ignored. Organoids have 3 main limitations. First, Current organoids are relatively simple and do have a vascular system. In vivo, tissues are penetrated and complex vascular networks interact to allow the exchange of oxygen, nutrients, waste, and different biochemical interactions between tissues. By contrast, in vitro, the microenvironment of organoids is still incomplete to a large extent. Second, current organoids do not include two critical components of immune factors and cells. Organoids cannot completely simulate the immune microenvironment of various tissues or diseases and lack the physiological process of mutual communication between the organoids and the surrounding immune environment, so they cannot completely simulate the complete response to the corresponding drugs or other treatments. Third, the culture of organoids is inseparable from the matrix, and the composition, structure, chemical, and physical characteristics of the matrix will affect the composition of organoids. However, no matrix meets the needs of this new in vitro model, which significantly limits the large-scale promotion and use of organoids. In the following section, we will focus on these shortcomings faced by similar organs, show the efforts made by scholars to break through the shackles, and point to future directions of research.

At present, organoids are still of micron size, and a particular gap still exists between their functions and normal tissues. A significant factor is the lack of a vascular system. When organoids grow to a certain extent, the cells in the center cannot get enough nutrition, and excretion of metabolic waste in the cells is difficult, limiting the popularization and application of organoids. Two main methods can be employed to construct vascularized organoids: one is “in vivo vascularization” by transplanting organoids into animal models, and the other is “in vitro vascularization,” which is implemented by combining gene editing, mixed cell culture, and microfluidic platform.

In in vivo vascularization, vascularized organoids are constructed by transplanting the organoids into the corresponding animal model to promote the connection between the host animal model and the transplanted organoid model through blood vessels. The kidney is one of the organs closest to human blood vessels. The total amount of plasma filtered by humans every day is as high as 200 L. In humans, wastes are removed through the kidneys to maintain the balance of water, acid–base, and electrolytes in the body. Human-derived kidney organoids can be used as disease model; however, a key question is whether a functional vascular system can be constructed. Van et al. found that renal organoids gradually formed a vascular system by transplanting hPSC-derived renal organoids into the renal capsule of immunodeficient mice, and microscopic examination confirmed a functional vascular network between the subcapsular organoids and host blood vessels (van den Berg et al., 2018) (Figure 4). In a follow-up study, after vascularization in the host, renal organoids showed glucan and albumin size selectivity on the glomerular filtration barrier and proximal tubular dextran reuptake (van den Berg et al., 2020). Organoids with functional blood vessels are closer to the actual condition of human tissues in terms of structure and function, so they can be more suitable for establishing disease models and for clinical applications in regenerative medicine. Similarly, organoids are transplanted into the abdominal cavity and brain of mice to establish blood circulation (Raikwar et al., 2015; Mansour et al., 2018; Soltanian et al., 2019).

In in vivo vascularization, organoids are simple to use and a vascular system can be constructed when combined with an animal model. However, the close relationship between the organoids and xenografts. The internal environment makes the organoids form a vascular system with perfusion ability and form a staggered whole with the surrounding tissue so that organoids are really alive. By contrast, this in vivo vascularization model still cannot eliminate the limitations of traditional xenograft animal models. Even more worrying is that when human organoids are transferred into an animal, the complex vascular system will continue to reconstruct organoids. Thus, whether animals will gradually replace the cells, matrix, and structure of organoids needs more research.

In vitro vascularization means promoting the vascularization of organoids in vitro through the mixed culture of different cells, genetic engineering, or construction of various physical and chemical environments without other animal models (Table 4). For example, in brain organoids, some scientists use genetic engineering to make human cortical organs express EVT2 (the known regulatory gene of angiogenesis) to obtain vascular organoids having the characteristics of the blood–brain barrier (Cakir et al., 2019). Some scientists co-culture human ESCs or human multifunctional cells with human umbilical vein endothelial cells in vitro to produce organoids with a well-developed reticular or tubular vascular system (Shi et al., 2020b). The co-culture method depends on the introduction of other external angioblasts, which are simple but difficult to control. By contrast, the gene-editing method relies on the overexpression of some cytokines and inevitably faces some disadvantages, such as low success rate, gene mutation, technical difficulty, and high cost. Therefore, obtaining organoids with vascular characteristics through gene editing and co-culture is considered sufficient, but these organoids only deliver some oxygen and nutrients and are quite different from actual perfusion vessels. These organoids still need to be transplanted into animals to make the blood vessels genuinely functional.

The traditional in vitro vascularization method is a 2D culture model that can only cultivate organoids in a pre-added medium under a single culture condition. The complex environment in the body, such as mechanical stress, variable concentrations of nutrient factors, and fluid circulation, is difficult to simulate. Organoids-on-a-chip is the most effective model to simulate human functions. Compared with the static control group, the vasculature of renal tubules and glomerulus was enriched, and maturity was enhanced during the development of renal organoids in the presence of blood flow (Homan et al., 2019). In other studies, retina-on-chip provides vascular-like perfusion and, for the first time, can recreate the interaction of mature photoreceptor segments with the retinal pigment epithelium in vitro and could replicate the pathological mechanism and drug reaction in vivo (Rajasekar et al., 2020). The flow of the culture medium is essential for the formation of blood vessels, and organoids-on-a-chip can achieve a higher level of self-assembly, genuinely restoring specific physiological functions, pathological patterns, and drug responses of the prototype organ. Furthermore, a microfluidic platform called IFlowPlate can be used to culture up to 128 independently perfused and vascularized colon organoids in vitro. Tissue extraction is allowed for downstream experimental analysis (Rajasekar et al., 2020). The study is an essential step for the large-scale promotion and use of vascularized organoids. The current microfluidic platform is crude and semi-adjustable but more compliant with the development direction of organoids. To simulate the internal environment as accurately as possible, factors such as shape, concentration of cytokine composition, and flow rate must be considered because they can affect the vascularization of organoids. The microfluidic platform needs to be combined with artificial intelligence. The future microfluidic platform includes but is not limited to the following features: sleek appearance; use of electronic mechanical timing and quantitative injection of new culture medium; adjustable flow rate and direction of liquids; adjustable temperature, humidity, oxygen, and carbon dioxide concentrations; a sensor placed in the tail detects the old culture medium; the injection process is adjusted according to the discharge liquid; and imaging technology monitors blood vessel development in organoids in real time. These features are more compliant with new in vitro, independent, specific, and controllable vascularized organoids pursued by scientists.

The immune system is an important system that performs immune response and immune function. This system comprises immune organs, immunocytes, and immune molecules, identifying and excluding foreign antigenic matter and coordinating with other body systems. Moreover, it maintains the stability of the environment and balances physiological processes within the body and is mainly involved in the development of various diseases. Traditional 2D cell lines can be co-cultured with different immune cells, but this is just a random mix and does not represent the communication between immune cells and other cells and does not characterize the immune microenvironment. If implanted in immunodeficient animals, xenografts limit the interaction between the host immune system and cancer cells. If implanted in immunocompetent animals, xenografts are easily mixed with inherent immune system cells of animals. In the following text, we will introduce the immune research of organoids from three aspects, including immune tissue construction, immune–epithelial interaction, and tumor immune microenvironment.

Since the development of organoids, scientists consider the thymus as the first immune organ. The thymus is a vital lymphoid organ located in the upper part of the anterior mediastinum behind the sternal stalk. Its function is to continuously produce various T-cell populations, which play essential roles in the body’s immune function. A study showed that transplantation of thymic organoids into non-thymic nude mice can effectively promote the homing of lymphocyte progenitor cells and support thymic hematopoiesis and immune response (Fan et al., 2015). Further, a recent study showed that combining epithelial–mesenchymal mixed cells with thymic interstitial cells and natural thymic acellular ECM can produce T-cells in humanized immunodeficient mice (Campinoti et al., 2020). These findings lay the foundation for cellular and molecular communications between ECM and thymocytes and provide a practical prospect for the construction of thymic organoids and thymus regeneration in vitro. These provide an opportunity to study tissue growth, development, and treatment of congenital and acquired immune diseases.

The interaction between epithelial cells and immune cells plays an essential role in the physiological balance in mammals. Integrating the interaction network of organoids, immune cells, and related cells is very important for tissue growth and development, establishment of related disease models, drug evaluation, pharmacological testing, and application in regenerative medicine.

In this section, we will discuss the interaction between intestinal epithelial organoids and the surrounding immune environment. In the physiological environment of the small intestine, to maintain the dynamic balance of tissues, the intestinal epithelium regenerates continuously from ISCs to eventually differentiate into intestinal epithelial cells, Paneth cells, tuft cells, etc. Through the experiment using co-culture of organoids with immune cells and related cytokines, different levels of interactions were found between intestinal epithelial organoids and the surrounding immune environment in vitro (Figure 5). Different immune cells and their cytokines play diverse positive and negative roles in this dynamic tissue balance. The intricate interactions between them are the primary conditions necessary for preventing and curbing pathogenic infections and preventing excessive immunoreactive and subsequent tissue damage repair processes (Thaiss et al., 2016). Moreover, many studies are still using co-cultures of single immune cells and organoids, which are far from the complex immune microenvironment of the human body.

Immune cells are essential components of the tumor microenvironment and control cancer progression and drug response (Greten and Grivennikov, 2019). The emergence of tumor immunotherapy also revolutionized cancer treatment and inspired extensive research on tumor immunology and on using this “natural weapon” to gain therapeutic benefits. The problem of applying organoid technology to establish a model of the interaction between tumor and immune cells needs to be solved first. At present, two primary sources of autologous immune cells introduced into the organoids are available. The first source is the mixed tumor/lymphocyte organoids produced by introducing lymph node components or peripheral blood lymphocytes into the tumor organoids, such as pancreatic ductal adenocarcinoma (Holokai et al., 2020), melanoma (Votanopoulos et al., 2020), and colon tumor (Courau et al., 2019). Those methods model the tumor immune circulation, but most of them used epithelial-only organoids co-cultured with lymphocytes. The immune microenvironment of different tumors varies; even the same tumors have different immune environments. Therefore, a simple mixture of tumor organoids and immune cells cannot obtain the immune microenvironment and cannot be used in the experimental immunotherapy model. The second method is to construct the organoids with an immune environment. Scientists placed the tumor tissue in the air–liquid interface (Neal et al., 2018) or 3D microfluidic culture system (Jenkins et al., 2018), and the results showed that tumor spheres retain the original autologous matrix, related immune checkpoint deletion, tumor-infiltrating lymphoids, and myeloid subsets. This method retains the complex histological structures with tumor parenchyma and stroma, including functional tumor-specific tumor-infiltrating lymphocytes, which can effectively predict tumor development, and the effect of PD-1 or PD-L1 inhibition could be assessed (Neal et al., 2018). However, this method still has limitations, existing culture conditions cannot meet the needs of tumor cells, stromal cells, and immune cells simultaneously, and the unique tumor immune microenvironment will be gradually lost in the culture process. In the future, the development of tumor immune organoids will aid in the immune-oncology study of patient-derived tumor organoids in a tumor-preserving microenvironment. Tumor organoids with an immune microenvironment can aid in the analysis of the pathology between tumor and immune cells, reproduce cancer-related inflammation and canceration, screen and optimize cellular immunotherapy in vitro, and shorten the absolute distance between the laboratory and clinic.

In addition, tumor organoids with immune–vascular interaction have made a breakthrough (Cui et al., 2018). This organoid model can be used to culture tumor cells, endothelial cells, and immune cells from patients in a controllable microenvironment, which is applied to the phenotypic identification of various tumors and allows high-throughput drug screening and real personalized drug screening possible and advances precision medicine a step forward.

ECM is a complex hierarchical network composed of proteins, which affect a series of cell processes, such as adhesion, proliferation, and differentiation. The construction of biomaterials that mimic natural ECM characteristics is significant for studying cell physiology (Zhu et al., 2019). Similarly, in the construction of organoids in vitro, the selection and construction of culture medium are also critical. The construction and selection standards of all kinds of in vitro model culture matrices are focused on whether the model can better simulate human physiological and functional environment on a multi-scale from molecule to cell, tissue, organ, and even the whole organism. A hydrogel is a multiphase matrix composed of hydrophilic polymers with high water content, which has a highly porous structure similar to the natural ECM. Hydrogels are recognized as the first choice for simulating biological ECM to construct organoids in vitro because of their high biocompatibility, extraordinary permeability, appropriate elasticity, and hardness (Liu et al., 2019). According to their composition, hydrogels can be roughly divided into natural, synthetic, and hybrid hydrogels (Table 5).